Expiratory Muscle Training for Persons With Neurodegenerative Disease (EMST)
|ClinicalTrials.gov Identifier: NCT00856518|
Recruitment Status : Completed
First Posted : March 5, 2009
Results First Posted : November 29, 2016
Last Update Posted : February 10, 2017
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease Multiple Sclerosis||Device: EMST Device: Sham||Phase 2 Phase 3|
The proposed investigation will:
Determine if 5 weeks of Expiratory Muscle Strength Training (EMST) increases maximal expiratory driving pressure (MEP) and improves swallow, cough and breathing function in individuals with PD and MS. Following the post assessment of the 5 week EMST program we will then evaluate three different modules for monitoring the continuation of the treatment while assessing patient quality of life and caregiver burden/satisfaction. This will help us determine if one particular home training method results in different physiological and functional outcomes.
Aim 1. Determine the effects of an EMST program on swallow function, voluntary cough production and breathing function in individuals with PD and MS identified as below normal limits for their age and sex (via physiological measures).
Hypothesis 1: There will significant and positive treatment effects following 5 weeks of EMST on the measures of swallow, cough production and breathing function in those with PD and MS following 5 weeks of treatment.
Aim 2: Determine the outcome of three uniquely structured home treatment monitoring programs in maintaining the EMST post treatment effect for patients with MS and PD. These programs are referred to as: Education Module (A), Question Only (B), and Education Module plus Question (C). The monitoring system will be provided by VitelNet, a leading provider of home health monitoring, clinician-based telemedicine Hypothesis 2: Program C will provide greater maintenance of the EMST treatment effect for both patient groups compared to programs A and B.
Aim 3: Determine the effects of the home monitoring programs for improving patient quality of life and caregiver burden/satisfaction.
Hypothesis 3: Program C will provide greater improvements in patient quality of life and caregiver burden compared to programs A and B.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||42 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Expiratory Muscle Training for Persons With Neurodegenerative Disease|
|Study Start Date :||March 2009|
|Actual Primary Completion Date :||August 2014|
|Actual Study Completion Date :||August 2014|
Active Comparator: Arm 1: EMST
The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
Other Name: EMST 150
Sham Comparator: Arm 2: Sham group
The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load
The same device just like the EMST but does not provide a load on the target muscle group
- Maximum Expiratory Pressure (MEP) [ Time Frame: at baseline and again after 5-week EMST exercise ]Expiratory pressure generating capacity assessed via handheld manometer.
- Penetration-Aspiration Scale Score [ Time Frame: at baseline and again after 5-week EMST exercise ]The Penetration-Aspiration Scale (PAS) was used to measure swallow safety. PAS is an 8 point ordinal scale for quantification of penetration and aspiration. PAS measures the depth to which material enters the airway and if the material is expelled following penetration or aspiration. Categorical groupings of PAS scores include "normal to mild" (1-2), "moderate" (3-5) and "severe" (6-8, indicating that material has passed into the lower airway). These PAS scores may be useful in denoting clinically significant changes (e.g. moderate to mild) resulting from treatment or disease progression. The following table reports the percentage of participants (out of the respective total group participants in EMST and Sham) with changed PAS score of 1 point or more (improving or worsening) and without PAS score changes from pre- to post treatment. The data represent an exploratory quantification without statistical analysis.
- Swallow-related Quality of Life (SWAL-QOL) [ Time Frame: at baseline and after 5-week of EMST exercise ]The SWAL-QOL is a validated and standardized tool that measures burden; symptom status including pharyngeal, oral, and saliva; fear; and mental health subdomains. Responses are determined according to an ordinal scale where 1 equals a severe problem and 5 equals no problem. The SWAL-QOL provides an overall score as well as subscale scores. Subjects rate quality of life as follows (expressed as percentage of the possible perfect score): little to no impact (81% - 100%), mild impact (61% - 80%), moderate impact (41% - 60%), severe impact (21% - 40%), and profound impact (0% - 20%).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00856518
|United States, Florida|
|North Florida/South Georgia Veterans Health System, Gainesville, FL|
|Gainesville, Florida, United States, 32608|
|Principal Investigator:||Janis J. Daly, PhD MS||North Florida/South Georgia Veterans Health System, Gainesville, FL|